Preclinical studies on [11C]TMSX for mapping adenosine A2A receptors by positron emission tomography

2003 ◽  
Vol 17 (3) ◽  
pp. 205-211 ◽  
Author(s):  
Kiichi Ishiwata ◽  
Wei-Fang Wang ◽  
Yuichi Kimura ◽  
Kazunori Kawamura ◽  
Kenji Ishii
Keyword(s):  
Positron Emission Tomography ◽  
Emission Tomography ◽  
Preclinical Studies ◽  
Adenosine A2a Receptors ◽  
A2a Receptors ◽  
Positron Emission ◽  
Adenosine A2a

Potential of [11C]TMSX for the evaluation of adenosine A2A receptors in the skeletal muscle by positron emission tomography

2004 ◽  
Vol 31 (7) ◽  
pp. 949-956 ◽  
Author(s):  
Kiichi Ishiwata ◽  
Masaki Mizuno ◽  
Yuichi Kimura ◽  
Kazunori Kawamura ◽  
Keiichi Oda ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Positron Emission Tomography ◽  
Emission Tomography ◽  
Adenosine A2a Receptors ◽  
A2a Receptors ◽  
Positron Emission ◽  
Adenosine A2a

First visualization of adenosine A2A receptors in the human brain by positron emission tomography with [11C]TMSX

Synapse ◽  
2004 ◽  
Vol 55 (2) ◽  
pp. 133-136 ◽  
Author(s):  
Kiichi Ishiwata ◽  
Masahiro Mishina ◽  
Yuichi Kimura ◽  
Keiichi Oda ◽  
Toru Sasaki ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Human Brain ◽  
Emission Tomography ◽  
Adenosine A2a Receptors ◽  
A2a Receptors ◽  
Positron Emission ◽  
Adenosine A2a

Carbon-11-labeled KF21213: a highly selective ligand for mapping CNS adenosine A2A receptors with positron emission tomography

2000 ◽  
Vol 27 (6) ◽  
pp. 541-546 ◽  
Author(s):  
Wei-Fang Wang ◽  
Kiichi Ishiwata ◽  
Hiromi Nonaka ◽  
Shin-ichi Ishii ◽  
Motohiro Kiyosawa ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Emission Tomography ◽  
Adenosine A2a Receptors ◽  
A2a Receptors ◽  
Positron Emission ◽  
Selective Ligand ◽  
Adenosine A2a

scholarly journals In Vivo Positron Emission Tomography Imaging of Adenosine A2A Receptors

2020 ◽  
Vol 11 ◽  
Author(s):  
Meng-Juan Sun ◽  
Fang Liu ◽  
Ya-Fei Zhao ◽  
Xiao-Ai Wu
Keyword(s):  
Positron Emission Tomography ◽  
Emission Tomography ◽  
Research Progress ◽  
Psychiatric Disease ◽  
Adenosine A2a Receptors ◽  
Pet Tracers ◽  
A2a Receptors ◽  
Positron Emission ◽  
Adenosine A2a

As an invasive nuclear medical imaging technology, positron emission tomography (PET) possess the possibility to imaging the distribution as well as the density of selective receptors via specific PET tracers. Inspired by PET, the development of radio-chemistry has greatly promoted the progress of innovative imaging PET tracers for adenosine receptors, in particular adenosine A2A receptors (A2ARs). PET imaging of A2A receptors play import roles in the research of adenosine related disorders. Several radio-tracers for A2A receptors imaging have been evaluated in human studies. This paper reviews the recent research progress of PET tracers for A2A receptors imaging, and their applications in the diagnosis and treatment of related disease, such as cardiovascular diseases, autoimmune diseases, neurodegenerative and psychiatric disease. The future development of A2A PET tracers were also discussed.

Quantification of adenosine A2A receptors in the human brain using [11C]TMSX and positron emission tomography

2006 ◽  
Vol 34 (5) ◽  
pp. 679-687 ◽  
Author(s):  
Mika Naganawa ◽  
Yuichi Kimura ◽  
Masahiro Mishina ◽  
Yoshitsugu Manabe ◽  
Kunihiro Chihara ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Human Brain ◽  
Emission Tomography ◽  
Adenosine A2a Receptors ◽  
A2a Receptors ◽  
Positron Emission ◽  
Adenosine A2a

Preclinical studies on [11C]MPDX for mapping adenosine A1 receptors by positron emission tomography

2002 ◽  
Vol 16 (6) ◽  
pp. 377-382 ◽  
Author(s):  
Kiichi Ishiwata ◽  
Tadashi Nariai ◽  
Yuichi Kimura ◽  
Keiichi Oda ◽  
Kazunori Kawamura ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Emission Tomography ◽  
Preclinical Studies ◽  
Adenosine A1 Receptors ◽  
Positron Emission ◽  
Adenosine A1

scholarly journals [18F]Fluorodeoxyglucose Positron Emission Tomography Correlates With Akt Pathway Activity but Is Not Predictive of Clinical Outcome During mTOR Inhibitor Therapy

2009 ◽  
Vol 27 (16) ◽  
pp. 2697-2704 ◽  
Author(s):  
Wen Wee Ma ◽  
Heather Jacene ◽  
Dongweon Song ◽  
Felip Vilardell ◽  
Wells A. Messersmith ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Fdg Pet ◽  
Mtor Inhibitor ◽  
Inhibitor Therapy ◽  
Emission Tomography ◽  
Preclinical Studies ◽  
Mtor Inhibition ◽  
Akt Activation ◽  
Positron Emission ◽  
Eortc Criteria

Purpose Positron emission tomography (PET) with [18F]fluorodeoxyglucose (FDG-PET) has increasingly been used to evaluate the efficacy of anticancer agents. We investigated the role of FDG-PET as a predictive marker for response to mammalian target of rapamycin (mTOR) inhibition in advanced solid tumor patients and in murine xenograft models. Patients and Methods Thirty-four rapamycin-treated patients with assessable baseline and treatment FDG-PET and computed tomography scans were analyzed from two clinical trials. Clinical response was evaluated according to Response Evaluation Criteria in Solid Tumors, and FDG-PET response was evaluated by quantitative changes and European Organisation for Research and Treatment of Cancer (EORTC) criteria. Six murine xenograft tumor models were treated with temsirolimus. Small animal FDG-PET scans were performed at baseline and during treatment. The tumors were analyzed for the expression of pAkt and GLUT1. Results Fifty percent of patients with increased FDG-PET uptake and 46% with decreased uptake had progressive disease (PD). No objective response was observed. By EORTC criteria, the sensitivity of progressive metabolic disease on FDG-PET in predicting PD was 19%. Preclinical studies demonstrated similar findings, and FDG-PET response correlated with pAkt activation and plasma membrane GLUT1 expression. Conclusion FDG-PET is not predictive of proliferative response to mTOR inhibitor therapy in both clinical and preclinical studies. Our findings suggest that mTOR inhibitors suppress the formation of mTORC2 complex, resulting in the inhibition of Akt and glycolysis independent of proliferation in a subset of tumors. Changes in FDG-PET may be a pharmacodynamic marker for Akt activation during mTOR inhibitor therapy. FDG-PET may be used to identify patients with persistent Akt activation following mTOR inhibitor therapy.

Sign in / Sign up

Export Citation Format

Share Document